Heron Therapeutics: HOPA 2016 (Heron Therapeutics) - Mar 26, 2016 - "A single APF530 SC injection provides sustained therapeutic granisetron concentration for ≥ 5 days"; "APF530, as part of a guideline-recommended 3-drug regimen, demonstrated superiority versus Ond in preventing delayed CINV after HEC and was well tolerated"; "Together with the earlier noninferiority trial, results suggest that a single SC injection of APF530 may be a convenient outpatient treatment option for preventing CINV after MEC or HEC"
Clinical data • Oncology
|